GLP-1 medications like Wegovy and Zepbound can cost nearly $1,000 per month at list price — but employer insurance plans and manufacturer savings programs can dramatically reduce your out-of-pocket burden. Learn how to navigate formulary tiers, survive prior authorization, and stack savings cards to make GLP-1 therapy financially sustainable for the long term.
Understanding how your employer's health plan formulary works is the first step to accessing affordable GLP-1 therapy — and knowing how to advocate for yourself can make all the difference.
Document your BMI (must be ≥30, or ≥27 with a qualifying comorbidity like hypertension or type 2 diabetes), a history of medically supervised weight loss attempts, and any related diagnoses your prescriber can include. Prior auth approval rates improve dramatically when your physician submits documentation of comorbidities alongside the prescription request. If denied, always appeal — roughly 40% of initial GLP-1 prior auth denials are overturned on first appeal.
Major employers including Amazon, JPMorgan Chase, Walmart, and Microsoft have added GLP-1 coverage for obesity-related weight management to their health plans since 2023. A 2024 KFF survey found that 47% of large employers (500+ employees) now cover GLP-1 medications for obesity — up from just 25% in 2022. Smaller employers are slower to adopt due to cost concerns, but competitive labor markets are pushing expansion. If your employer doesn't currently cover GLP-1, submitting a formal benefits proposal to HR citing productivity and reduced downstream healthcare costs has worked for many employees at mid-size firms in cities like Austin, Denver, and Seattle.
Employer BenefitsCigna and Evernorth typically place Ozempic on Tier 3 (preferred brand) and Wegovy on Tier 4 (non-preferred) for commercial plans, meaning copays range from $150–$400/month even with coverage. Aetna's commercial plans frequently cover Mounjaro for diabetes (Tier 3) but exclude Zepbound unless the employer explicitly adds it. Blue Cross Blue Shield plans vary dramatically by state affiliate — BCBS of Texas and BCBS of Illinois are among the more GLP-1-friendly, while some BCBS plans in rural states have blanket obesity drug exclusions. Always call the member services number on your card and ask specifically: "Is [drug name] covered for the diagnosis of obesity (ICD-10 E66.9)?"
Insurance FormulariesUnitedHealthcare and its OptumRx pharmacy benefit management arm often require step therapy for GLP-1 coverage — meaning patients must have documented failure on at least one other weight loss intervention (typically 3–6 months of a structured program) before GLP-1 approval. Physicians in major metros like New York City, Los Angeles, and Chicago who specialize in obesity medicine have become expert at compiling step therapy documentation efficiently. UnitedHealth's 2024 policy update expanded GLP-1 coverage to all fully-insured commercial plans where BMI ≥30, but self-insured employer plans (common at large corporations) set their own formularies independently of UnitedHealth's defaults.
Step TherapyIf your employer plan doesn't cover GLP-1 medications, you have more leverage than you think. HR departments respond to data: the estimated ROI on employer GLP-1 coverage is $1.30 saved in downstream healthcare costs for every $1 spent, per a 2024 analysis by Milliman. Bring your physician's documentation, a written request citing the employer's stated wellness objectives, and any company wellness portal incentives. Employee benefits advocacy organizations like the National Alliance of Mental Illness and the Obesity Action Coalition offer template letters employees can customize for HR submissions. Employers in competitive hiring markets — particularly in tech, finance, and healthcare sectors in San Francisco, Boston, and New York — have added GLP-1 coverage specifically to attract talent.
HR AdvocacyPrior authorization (PA) for GLP-1 medications typically takes 3–14 business days and requires your prescriber to submit clinical documentation. Working with a physician experienced in obesity medicine significantly improves approval rates and turnaround time.
Even without insurance coverage, manufacturer savings cards, patient assistance programs, and third-party discount services can make GLP-1 medications accessible — but each comes with important eligibility rules.
Novo Nordisk offers a savings card for Wegovy that reduces cost to as low as $0/month for eligible commercially insured patients, and a separate card for Ozempic that caps costs at $99/month. Eligibility requires commercial insurance (government insurance like Medicare/Medicaid makes patients ineligible for manufacturer savings cards). Cards are available at WegovySavings.com and OzempicSavings.com. Income thresholds apply for the uninsured Wegovy patient assistance program — households earning up to 400% of the federal poverty level (~$60,240 for a single person in 2024) may qualify for free or reduced-cost medication through Novo Nordisk's patient assistance program (PAP).
Novo NordiskEli Lilly's savings programs for Mounjaro and Zepbound are among the most aggressive in the GLP-1 space. The Zepbound Savings Card offers commercially insured patients costs as low as $25/month for a 1-month supply and $50/month for a 3-month supply — extraordinary value given the $1,059 monthly list price. Lilly's LillyInsulinValue program (now expanded to GLP-1s) also offers Mounjaro to qualifying uninsured or underinsured patients through the Lilly Cares Foundation at no cost. These programs are available nationwide; patients in rural areas of states like Montana, Wyoming, and Mississippi who lack nearby specialty care can enroll entirely online through LillyCares.com.
Eli LillyGoodRx pricing for Ozempic typically runs $850–$920 per month without insurance — only marginally below list price — making it most useful for bridging coverage gaps rather than as a primary cost strategy. However, GoodRx's free membership tier and Gold membership ($9.99/month) can occasionally surface significant discounts at specific pharmacy chains, and the platform's price comparison across CVS, Walgreens, Rite Aid, Costco, and Sam's Club pharmacies is genuinely useful. Blink Health and RxSaver offer similar comparison tools. For compounded semaglutide and tirzepatide (legal during FDA shortage periods), some telehealth platforms offer cash-pay rates of $200–$400/month — significantly below branded options.
Discount ServicesCost Plus Drugs (costplusdrugs.com), founded by Mark Cuban, applies a transparent 15% markup over manufacturing cost to generic medications. While brand-name semaglutide and tirzepatide are not yet available as generics, Cost Plus Drugs has been vocal about plans to offer generic GLP-1s once patents expire (the earliest Ozempic patent expiration is projected for 2031). In the meantime, Cost Plus Drugs sells metformin (a first-line diabetes and weight management medication) for $5/month — useful as an adjunct. Additionally, some independent compounding pharmacies listed on PCAB-accredited registries offer tirzepatide at reduced rates for patients with documented financial hardship; your prescriber can provide a letter of medical necessity to facilitate access.
Alternative PricingGLP-1 insurance coverage and employer benefits vary significantly by geography. States with strong obesity medicine advocacy — including California, New York, Massachusetts, and Washington — tend to have more commercially insured patients with GLP-1 formulary access. Texas and Florida, with large self-insured employer populations, show wide variation: major metros like Houston, Dallas, Miami, and Orlando have robust employer coverage, while rural regions lag. The Southeast, including states like Alabama, Mississippi, and Georgia, has the highest rates of obesity-related comorbidities but some of the least generous GLP-1 formulary inclusion. Midwest employers in Chicago, Minneapolis, and Detroit have increased GLP-1 coverage rapidly since 2023. Patients in all 50 states can access manufacturer savings programs and patient assistance programs regardless of local insurance landscape, making these national programs a critical safety net.